Condition: Myocardial Injury · LV Dysfunction · Coronary Artery Disease · Sponsor: Ralf Rothoerl
To investigate patients suffering from iHF and a LVEF of equal or less than 40% despite best medical treatment safety and efficacy of a single retrograde intra-cardiac venous (i.cv.) injection of UA-ADRCs isolated from lipoaspirate at the point of care, using the Transpose® RT / Matrase System (InGeneron, Houston, TX, USA) through an over-the- wire, small balloon catheter, advanced through the coronary si-nus and located within a coronary vein at the site of inter-est, versus patients on best medical treatment.
This description comes directly from the study's public registry record.
Anastassiya Ganina-Smelova, PhD · +77024346421 · anastassiya_smelova@mail.ru
Aizhan Akhaeva, PhD · +77075008522 · akhaeva@mail.ru
Always discuss trial participation with your own doctor first.
| National Scientific Medical Center | Astana, Kazakhstan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06705023